3,142 results match your criteria Current Opinion in Rheumatology[Journal]


Changing rates in fracture trends are temporally associated with declining testing and treatment: reality or ecologic fallacy?

Curr Opin Rheumatol 2019 May;31(3):316-320

Department of Epidemiology.

Purpose Of Review: The changing patterns of osteoporosis treatment and fragility fractures have led to what leaders are calling a 'crisis in the osteoporosis.' We address data on changing patterns in fractures, and highlight strengths and limitations of recently published data.

Recent Findings: Declines in hip fracture rates have been shown in studies from around the world. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000596DOI Listing
May 2019
3 Reads

Joints for joints: cannabinoids in the treatment of rheumatoid arthritis.

Curr Opin Rheumatol 2019 May;31(3):271-278

Poliklinik, Funktionsbereich & Hiller Forschungszentrum für Rheumatologie, University Hospital Duesseldorf, Duesseldorf, Germany.

Purpose Of Review: An increasing number of patients with rheumatoid arthritis (RA) are using cannabis to treat their symptoms, although systematic studies regarding efficacy in RA are lacking. Within this review we will give an overview on the overall effects of cannabinoids in inflammation and why they might be useful in the treatment of RA.

Recent Findings: Peripherally, cannabinoids show anti-inflammatory effects by activating cannabinoid type 2 receptors (CB2) which decrease cytokine production and immune cell mobilization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000590DOI Listing
May 2019
3 Reads

Treatment of neuromyelitis optica spectrum disorders.

Curr Opin Rheumatol 2019 May;31(3):250-255

Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA.

Purpose Of Review: This review discusses concepts for diagnosing neuromyelitis optica spectrum disorders (NMOSD), distinguishing NMOSD from other inflammatory diseases of the central nervous system, and highlights recent and forthcoming data on acute and maintenance therapy of NMOSD.

Recent Findings: The neurologic manifestations of NMOSD are heterogenous, extending beyond classic presentations of optic neuritis and longitudinally extensive transverse myelitis. NMOSD may be comorbid with rheumatologic diseases, such as systemic lupus erythematosus, but is recognized as a distinct entity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000603DOI Listing
May 2019
1 Read

Pathogenesis and treatment of autoimmune rheumatic diseases.

Curr Opin Rheumatol 2019 May;31(3):307-315

Division of Rheumatology, Departments of Medicine, Microbiology and Immunology, Biochemistry and Molecular Biology, State University of New York, Upstate Medical University, College of Medicine, Syracuse, New York, USA.

Purpose Of Review: Autoimmune diseases are of unknown origin, and they represent significant causes of morbidity and mortality. Here, we review new developments in the understanding of their pathogenesis that have led to development of well tolerated and effective treatments.

Recent Findings: In addition to the long-recognized genetic impact of the HLA locus, interferon regulatory factors, PTPN22, STAT4, and NOX have been implicated in pathogenesis of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00002281-201905000-0001
Publisher Site
http://dx.doi.org/10.1097/BOR.0000000000000594DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447054PMC
May 2019
4 Reads

Perioperative management of immunosuppression in patients with rheumatoid arthritis.

Curr Opin Rheumatol 2019 May;31(3):300-306

Division of Rheumatology, University of Pennsylvania.

Purpose Of Review: Patients with rheumatoid arthritis are at increased risk of infection after surgery. Recent literature has provided more data and updated guidelines to guide the management of immunosuppression in the perioperative period.

Recent Findings: Studies over the past few years have confirmed that patients with rheumatoid arthritis are at increased risk of infection after surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000589DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446585PMC
May 2019
2 Reads
4.886 Impact Factor

Treatment of primary and secondary immune thrombocytopenia.

Curr Opin Rheumatol 2019 May;31(3):213-222

Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, USA.

Purpose Of Review: Medical therapies for the treatment of immune thrombocytopenia (ITP) complicating SLE are increasingly being investigated as alternatives to splenectomy and IVIG. The purpose of this review is to highlight the therapies that are utilized in the treatment of primary ITP and ITP secondary to lupus.

Recent Findings: Corticosteroids are still the standard initial treatment of ITP, with the addition of IVIG when a rapid response is needed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000599DOI Listing
May 2019
1 Read

Management of scleroderma renal crisis.

Authors:
Vivek Nagaraja

Curr Opin Rheumatol 2019 May;31(3):223-230

Division of Rheumatology and Scleroderma Program, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.

Purpose Of Review: Scleroderma renal crisis (SRC) is a life-threatening manifestation in systemic sclerosis (SSc) and is usually presented by an acute onset of severe hypertension together with an acute kidney injury. We can conceptualize SRC as a systemic syndrome with features that extend beyond the involvement of the kidney. The goal of this review is to inform clinicians about the risk factors for SRC in patients with SSc and to emphasize the importance of early identification and initiation of treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000604DOI Listing
May 2019
2 Reads

Opioid use in rheumatoid arthritis: trends, efficacy, safety, and best practices.

Curr Opin Rheumatol 2019 May;31(3):264-270

Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Purpose Of Review: The opioid epidemic remains prominent in both the medical literature and popular media. Rheumatologists are among the physicians at the forefront of the epidemic because of the prominent role of pain in rheumatoid arthritis (RA) and the limited options for treatment of pain. The purpose of this review is to provide an update on the trends of opioid use among patients with RA, to discuss the various mechanisms of RA pain, review the available evidence for opioid efficacy in RA, and to promote a guideline for best practices in opioid prescribing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000602DOI Listing
May 2019
6 Reads

Arthritis risk with immune checkpoint inhibitor therapy for cancer.

Curr Opin Rheumatol 2019 May;31(3):293-299

Department of General Internal Medicine, Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, USA.

Purpose Of Review: This review summarizes the current evidence on inflammatory arthritis following cancer treatment with immune checkpoint inhibitors (ICI), and the effects of these therapies in patients with preexisting autoimmune arthritis.

Recent Findings: As the use of ICI for cancer therapy continues to expand, a myriad of immune-related adverse events (irAE) caused by these therapies are being recognized. Arthritis has been increasingly reported as a de novo irAE, presenting sometimes as a well defined disorder, such as rheumatoid arthritis or psoriatic arthritis, and in other occasions as undifferentiated monoarthritis, oligoarthritis, or polyarthritis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000601DOI Listing
May 2019
4 Reads
4.886 Impact Factor

Management of systemic sclerosis-associated interstitial lung disease.

Curr Opin Rheumatol 2019 May;31(3):241-249

Department of Internal Medicine, Division of Rheumatology, Scleroderma Program.

Purpose Of Review: To review the recently published data and provide a practical overview for management of systemic sclerosis-interstitial lung disease (SSc-ILD).

Recent Findings: Published evidence shows considerable practitioner variability in screening patients for ILD. Recent published data support use of cyclophosphamide or mycophenolate mofetil as first-line treatment of SSc-ILD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000592DOI Listing
May 2019
3 Reads

Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?

Curr Opin Rheumatol 2019 May;31(3):285-292

Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, The University of Manchester.

Purpose Of Review: There are currently several available biologics for rheumatoid arthritis (RA) with similar efficacy in most trials. A major consideration therefore in choosing a biologic, continues to be safety concerns such as infection. Considerable advances have been made in the understanding of biologic safety on a population level; however, how close are we to stratifying risk for individual patients? This review discusses evidence published in the last year, with reference to key previous literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000598DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443047PMC
May 2019
11 Reads

Depression and the risk of rheumatoid arthritis.

Curr Opin Rheumatol 2019 May;31(3):279-284

Department of Community Health Sciences.

Purpose Of Review: Rheumatoid arthritis (RA) is associated with negative changes in mental health. This is generally attributed to symptoms of inflammation and the adverse impact of RA on quality of life and functioning. Until recently, causal pathways in the opposite direction have not been fully appreciated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000597DOI Listing
May 2019
1 Read

Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome.

Curr Opin Rheumatol 2019 May;31(3):231-240

Division of Rheumatology, Department of Internal Medicine, University of Michigan.

Purpose Of Review: Although antiphospholipid syndrome (APS) is best known for conveying increased risk of thrombotic events and pregnancy morbidity, thrombocytopenia is also recognized as a common association. In this review, we will explore the relationship between thrombocytopenia and APS, highlighting our evolving understanding - and persistent knowledge gaps - through clinically oriented questions and answers.

Recent Findings: A history of thrombocytopenia likely portends a more severe APS phenotype (including increased risk of thrombosis). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000595DOI Listing
May 2019
2 Reads

Patient preferences for rheumatoid arthritis treatment.

Curr Opin Rheumatol 2019 May;31(3):256-263

Yale University School of Medicine, New Haven.

Purpose Of Review: To provide an overview of recent articles discussing patient preferences for rheumatoid arthritis (RA) treatment.

Recent Findings: Recent studies examined patient preferences for RA treatment in several populations, finding that most participants were willing to accept certain risks of adverse effects to gain potential benefits. Perspectives regarding cannabis were studied, with patients describing medical marijuana as an alternative therapy to be used with prescription medications or as means of tapering off these medications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000591DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438722PMC
May 2019
8 Reads

Gene-function studies in systemic lupus erythematosus.

Curr Opin Rheumatol 2019 Mar;31(2):185-192

Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán.

Purpose Of Review: The aim of this review is to discuss recent developments in our understanding of how systemic lupus erythematosus (SLE)-associated genes contribute to autoimmunity.

Recent Findings: Gene-function studies have revealed mechanisms through which SLE-associated alleles of IFIH1, TNFAIP3, IRF5, and PRDM1 likely contribute to the development of autoimmunity. Novel research has identified Mac-1 (encoded by ITGAM), CaMK4, and iRhom2 as plausible therapeutic targets in lupus nephritis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000572DOI Listing
March 2019
2 Reads

The microbiome in systemic autoimmune disease: mechanistic insights from recent studies.

Curr Opin Rheumatol 2019 Mar;31(2):201-207

Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.

Purpose Of Review: The resident bacterial communities and the host immune system have coevolved for millennia. However, recent changes in modern societies have disrupted this coevolutionary homeostasis and contributed to a rise in immune-mediated conditions. The purpose of this review is to provide an overview of recently elucidated mechanisms of how certain taxa within the bacterial microbiome propagate autoimmunity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000574DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408954PMC
March 2019
15 Reads

Measuring outcomes in ankylosing spondylitis: pearls and pitfalls.

Curr Opin Rheumatol 2019 Mar;31(2):109-117

Allergy, Immunology Division, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York, USA.

Purpose Of Review: Patients with ankylosing spondylitis (AS) warrant a comprehensive clinical assessment because of the lack of biomarkers of disease activity, prognosis and response to biologic therapy. Multiple AS-related questionnaires have been developed to assess the disease status accurately, but feasibility remains a problem in clinical practice. The purpose of this review is to assess the pearls and pitfalls of AS-related outcome measures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000588DOI Listing
March 2019
4 Reads

Methods for measuring patient preferences: an update and future directions.

Curr Opin Rheumatol 2019 Mar;31(2):125-131

Department of Biomedical Informatics, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

Purpose Of Review: The current review highlights the growing number of available methods used to measure patient preferences and discusses how this impacts preference research in rheumatology. Spurred by the growing role of preferences in regulatory decisions and drug development, researchers have begun applying preference methods to study questions beyond the clinical context. We explore these trends, provide case studies highlighting changes in measuring patient preferences, compare strengths and weaknesses of common stated-preference methods, and discuss considerations for the future use of these methods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000587DOI Listing
March 2019
6 Reads

Quality improvement initiatives in rheumatology: an integrative review of the last 5 years.

Curr Opin Rheumatol 2019 Mar;31(2):98-108

Division of Rheumatology, Department of Medicine, University of California, San Francisco, California, USA.

Purpose Of Review: We reviewed recent quality improvement initiatives in the field of rheumatology to identify common strategies and themes leading to measurable change.

Recent Findings: Efforts to improve quality of care in rheumatology have accelerated in the last 5 years. Most studies in this area have focused on interventions to improve process measures such as increasing the collection of patient-reported outcomes and vaccination rates, but some studies have examined interventions to improve health outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000586DOI Listing
March 2019
18 Reads

Editorial: Updates in crystal deposition diseases.

Authors:
Sara K Tedeschi

Curr Opin Rheumatol 2019 Mar;31(2):132-133

Brigham and Women's Hospital, Division of Rheumatology, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000581DOI Listing
March 2019
1 Read

The vitamin D and calcium controversy: an update.

Curr Opin Rheumatol 2019 Mar;31(2):91-97

Deakin University, Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Geelong, Melbourne, Australia.

Purpose Of Review: Calcium and vitamin D supplementation is widely recommended for prevention of falls and fracture, particularly in the elderly where calcium intakes and vitamin D levels are often inadequate. A number of meta-analyses have questioned the benefits of untargeted or 'holistic' supplementation for falls and fracture, and raised the possibility of adverse cardiovascular effects. This review provides an update on these controversies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000584DOI Listing
March 2019
12 Reads

Diagnostic advances in synovial fluid analysis and radiographic identification for crystalline arthritis.

Curr Opin Rheumatol 2019 Mar;31(2):134-143

Purpose Of Review: The present review addresses diagnostic methods for crystalline arthritis including synovial fluid analysis, ultrasound, and dual energy CT scan (DECT).

Recent Findings: There are new technologies on the horizon to improve the ease, sensitivity, and specificity of synovial fluid analysis. Raman spectroscopy uses the spectral signature that results from a material's unique energy absorption and scatter for crystal identification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000582DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377265PMC
March 2019
2 Reads

Gout and cardiovascular disease: crystallized confusion.

Curr Opin Rheumatol 2019 Mar;31(2):118-124

Crystal Diseases Study Group, Division of Rheumatology, New York University School of Medicine, New York, USA.

Purpose Of Review: Gout is associated with the risk of cardiovascular morbidity and mortality, but the biological relationship between the two remains uncertain. The demonstration of reduction of cardiovascular risk with appropriate gout treatment would argue for a causal role for gout in cardiovascular disease. We reviewed recent studies that address the relationship between gout and cardiovascular disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000585DOI Listing
March 2019
2 Reads

The role of febuxostat in gout.

Curr Opin Rheumatol 2019 Mar;31(2):152-158

Department of Rheumatology, Hôpital Lariboisière, APHP.

Purpose Of Review: Concerns about the cardiovascular safety of febuxostat lead to reconsideration of the place of febuxostat in the management of gout.

Recent Findings: The CARES trial is a randomized controlled trial mandated by the FDA to compare the cardiovascular safety of febuxostat and allopurinol in the management of gout. About 6190 patients with gout and major cardiovascular disease, randomly assigned to allopurinol or febuxostat, were prospectively followed up for a median of 32 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000573DOI Listing
March 2019
4 Reads

Patient perspectives in gout: a review.

Curr Opin Rheumatol 2019 Mar;31(2):159-166

Medicine Service, VA Medical Center.

Purpose Of Review: Recent studies have produced evidence regarding the patient perspectives in gout including from disease experience to disease outcomes. Therefore, an overview on the topic can help improve our understanding of the patient experience.

Recent Findings: This article explores several aspects of the patient perspective including the impact of gout on a patient's life, patient knowledge and beliefs regarding gout and its treatments, patient-perceived barriers to optimal medication adherence in gout and patient's perception of their gout. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000583DOI Listing
March 2019
10 Reads

Genetic advances in gout: potential applications in clinical practice.

Curr Opin Rheumatol 2019 Mar;31(2):144-151

Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland.

Purpose Of Review: Many novel genetic associations in the field of hyperuricaemia and gout have been described recently. This review discusses advances in gout genetics and their potential clinical applications.

Recent Findings: Genome-wide association studies have identified approximately 30 serum urate-associated loci, some of which represent targets for drug development in gout. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000571DOI Listing
March 2019
5 Reads

The immune podocyte.

Curr Opin Rheumatol 2019 Mar;31(2):167-174

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

Purpose Of Review: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus and is characterized by proteinuria and renal failure. Proteinuria is a marker of poor prognosis and is attributed to podocyte loss and dysfunction. It is often debated whether these cells are innocent bystanders or active participants in the pathogenesis of glomerulonephritis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000578DOI Listing
March 2019
3 Reads

Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus.

Curr Opin Rheumatol 2019 Mar;31(2):208-212

Department of Rheumatology and Clinical Immunology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany.

Purpose Of Review: To provide an overview behind the concept and recent advances of low-dose interleukin-2 (IL-2) therapy in systemic lupus erythematosus (SLE).

Recent Findings: A disruption of regulatory T cell homeostasis caused by an acquired deficiency of IL-2 is a crucial event in the pathogenesis of SLE. Here, we highlight the key rationales for the clinical translation of low-dose IL-2 therapy in SLE and summarize the main findings from two independent, early phase uncontrolled clinical studies that investigated the immunological and clinical responses to low-dose IL-2 therapy in patients with active SLE. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00002281-201903000-0001
Publisher Site
http://dx.doi.org/10.1097/BOR.0000000000000575DOI Listing
March 2019
5 Reads

Neutrophils in lupus nephritis.

Curr Opin Rheumatol 2019 Mar;31(2):193-200

Center for Excellence in Vascular Biology, Department of Pathology, Brigham and Women's Hospital & Harvard Medical School, Boston, USA.

Purpose Of Review: Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease characterized by IgG-autoantibodies to nuclear antigens that can deposit in the kidney and trigger lupus nephritis. Neutrophils accumulate in the kidneys of patients with proliferative LUPUS NEPHRITIS and neutrophil products and a subset of granulocytes, called low-density granulocytes (LDG) may contribute to lupus nephritis pathogenesis. Here, we will discuss recent studies implicating neutrophils in the pathogenesis of human SLE nephritis and then examine studies that provide mechanistic insights into how these cells are recruited to the glomerulus following immune complex deposition and how their products may promote lupus nephritis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000577DOI Listing
March 2019
3 Reads

Postactivated B cells in systemic lupus erythematosus: update on translational aspects and therapeutic considerations.

Curr Opin Rheumatol 2019 Mar;31(2):175-184

Department of Medicine/Rheumatology and Clinical Immunology.

Purpose Of Review: This review summarizes recent insights and current understanding of the role of postactivated B cells in SLE and related pathogenic and potential therapeutic implications.

Recent Finding: B cells are considered key players in SLE and experience from various B-cell-targeted therapies underlines their clinical relevance. In the last years, new insights have been obtained on B-cell abnormalities within the complex pathophysiology of SLE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000576DOI Listing
March 2019
3 Reads

Gene-function studies in SLE.

Curr Opin Rheumatol 2018 Dec 11. Epub 2018 Dec 11.

Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán.

Purpose Of Review: The aim of this review is to discuss recent developments in our understanding of how systemic lupus erythematosus (SLE)-associated genes contribute to autoimmunity.

Recent Findings: Gene-function studies have revealed mechanisms through which SLE-associated alleles of IFIH1, TNFAIP3, IRF5, and PRDM1 likely contribute to the development of autoimmunity. Novel research has identified Mac-1 (encoded by ITGAM), CaMK4, and iRhom2 as plausible therapeutic targets in lupus nephritis. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00002281-900000000-9909
Publisher Site
http://dx.doi.org/10.1097/BOR.0000000000000572DOI Listing
December 2018
23 Reads

Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: biochemical markers associated with emerging clinical phenotypes and molecular endotypes.

Curr Opin Rheumatol 2019 Jan;31(1):80-89

The D-BOARD FP7 Consortium.

Purpose Of Review: This review focuses on the molecular taxonomy of osteoarthritis from the perspective of molecular biomarkers. We discuss how wet biochemical markers may be used to understand disease pathogenesis and progression and define molecular endotypes of osteoarthritis and how these correspond to clinical phenotypes.

Recent Findings: Emerging evidence suggests that osteoarthritis is a heterogeneous and multifaceted disease with multiple causes, molecular endotypes and corresponding clinical phenotypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000567DOI Listing
January 2019
20 Reads

Vasculitis and peripheral neuropathy.

Curr Opin Rheumatol 2019 Jan;31(1):40-45

Division of Rheumatology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.

Purpose Of Review: Vasculitis of medium-sized and small vessels commonly affects peripheral nerves and can occur in context of a systemic vasculitis with multiorgan involvement or a nonsystemic vasculitis limited to the peripheral nervous system. This review summarizes the clinical and pathological features of systemic and nonsystemic vasculitis of the peripheral nervous system.

Recent Findings: Vasculitis of peripheral nerves is a diffuse process that affects the vasa nervorum along the entire length of affected nerves but appears to cause injury primarily in a zone in the proximal-middle of the nerve that is particularly susceptible to ischemic injury. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000559DOI Listing
January 2019
1 Read

Management of large-vessel vasculitis.

Curr Opin Rheumatol 2019 Jan;31(1):25-31

Department of Internal Medicine, Division of Rheumatology, School of Medicine, Istanbul University - Cerrahpasa, Istanbul, Turkey.

Purpose Of Review: Glucocorticoids are the mainstay of therapy for large-vessel vasculitis, but potential toxicity and frequent relapses led to studies with nonbiologic and biologic glucocorticoid-sparing agents. The aim of this review is to discuss the recent evidence for the management of giant cell arteritis (GCA) and Takayasu arteritis (TAK).

Recent Findings: Tocilizumab proved to be a powerful glucocorticoid-sparing agent for GCA in a randomized placebo-controlled trial, whereas the trials with tocilizumab and abatacept failed to show a significant difference from placebo in relapse-free survival rate in TAK. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000561DOI Listing
January 2019
18 Reads

The role of complement in antineutrophil cytoplasmic antibody-associated vasculitis.

Curr Opin Rheumatol 2019 Jan;31(1):3-8

Department of Pathology.

Purpose Of Review: To provide a comprehensive overview of the current insight into the role of complement activation in antineutrophil cytoplasmic antibody-associated vasculitis (AAV). In addition, the therapeutic options targeting the complement system in AAV are discussed.

Recent Findings: It has become increasingly clear that complement, and more specifically signalling through the C5a receptor, contributes to the immunopathology of AAV. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000557DOI Listing
January 2019
21 Reads

New insights into IgG4-related disease: emerging new CD4+ T-cell subsets.

Curr Opin Rheumatol 2019 Jan;31(1):9-15

Department of Human Immunology, Research Institute for Frontier Medicine.

Purpose Of Review: New insights into IgG4-related disease (IgG4-RD) have recently been obtained. A better understanding of the mechanisms underlying this disease is important for identification of therapeutic targets, which will lead to the development of specific strategies for treatment.

Recent Findings: Infiltration of activated T follicular helper (Tfh) cells is observed in affected tissues of IgG4-RD. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00002281-900000000-9909
Publisher Site
http://dx.doi.org/10.1097/BOR.0000000000000558DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254779PMC
January 2019
20 Reads

Editorial: A review of vasculitis 2019: an introduction.

Curr Opin Rheumatol 2019 Jan;31(1):1-2

Department of Medicine (Rheumatology), New York University School of Medicine.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000565DOI Listing
January 2019
2 Reads

Nervous system involvement in Behçet's syndrome.

Curr Opin Rheumatol 2019 Jan;31(1):32-39

Department of Neurology, Istanbul University Cerrahpaşa School of Medicine, Istanbul, Turkey.

Purpose Of Review: Neurological involvement in Behçet's syndrome is defined as 'the occurrence of neurological symptoms and signs in a patient who meets the International Diagnostic Criteria for BS not otherwise explained by any other known systemic or neurological disease or treatment, and in whom objective abnormalities consistent with neuro-Behçet's syndrome (NBS) are detected either on neurological examination, neuroimaging studies (magnetic resonance imaging [MRI]), and/or on cerebrospinal fluid (CSF) examination'. Given that the neurological involvement of Behçet's syndrome carries a poor prognosis, we aimed to describe the differential diagnosis of NBS and highlight the different radiological patterns together with the treatment options.

Recent Findings: Two distinct MRI patterns of spinal cord involvement in Behçet's syndrome according to T2-weighted axial images were described: 'Bagel Sign' pattern: a central lesion with hypointense core and hyperintense rim with or without contrast enhancement; and 'Motor Neuron' pattern: a symmetric involvement of the anterior horn cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000562DOI Listing
January 2019
18 Reads

Cardiovascular magnetic resonance in the diagnosis and management of cardiac and vascular involvement in the systemic vasculitides.

Curr Opin Rheumatol 2019 Jan;31(1):16-24

Arthritis Research UK Centre for Epidemiology, Manchester University, Manchester, UK.

Purpose Of Review: Cardiac manifestations in systemic vasculitides, either primary or secondary due to infection, malignancy or autoimmune rheumatic diseases may be life-threatening. Cardiovascular (CVD) magnetic resonance (CMR) has been recently proposed as an ideal noninvasive tool to evaluate systemic vasculitides. In the present article, we present an overview of CMR in the diagnosis and follow-up of cardiac involvement in systemic vasculitides. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000560DOI Listing
January 2019
15 Reads

The ties that bind: skin, gut and spondyloarthritis.

Curr Opin Rheumatol 2019 Jan;31(1):62-69

Unit Molecular Immunology and Inflammation, Inflammation Research Institute VIB-Ghent University.

Purpose Of Review: This article aims to review recent literature linking epithelial barrier inflammation and arthritis in spondyloarthritis (SpA), with a critical view on how they are bound by genetic, immunological and environmental ties.

Recent Findings: The epithelia-joint axis has become an intense area of both basic and clinical SpA research. The penultimate goal is to understand the immunopathologic links between epithelial inflammation and arthritis in SpA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000569DOI Listing
January 2019
22 Reads

Sex bias in autoimmunity.

Curr Opin Rheumatol 2019 Jan;31(1):53-61

Department of Dermatology.

Purpose Of Review: To give an overview of recently published articles addressing the mechanisms underlying sex bias in autoimmune disease.

Recent Findings: Recent studies investigating the origins of sex bias in autoimmune disease have revealed an extensive and interconnected network of genetic, hormonal, microbial, and environmental influences. Investigation of sex hormones has moved beyond profiling the effects of hormones on activity and prevalence of immune cell types to defining the specific immunity-related genes driving these changes. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00002281-900000000-9910
Publisher Site
http://dx.doi.org/10.1097/BOR.0000000000000564DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296774PMC
January 2019
19 Reads

An update on the nomenclature for cutaneous vasculitis.

Curr Opin Rheumatol 2019 Jan;31(1):46-52

Section of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.

Purpose Of Review: Cutaneous vasculitis reflects a spectrum ranging from skin limited to severe systemic forms. To date, there is still no generally acknowledged nomenclature for cutaneous vasculitis. This review aims to summarize the recent advances in the nomenclature of cutaneous vasculitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000563DOI Listing
January 2019
10 Reads

Osteoarthritis following meniscus and ligament injury: insights from translational studies and animal models.

Curr Opin Rheumatol 2019 Jan;31(1):70-79

Department of Orthopaedic Surgery, Musculoskeletal Research Center.

Purpose Of Review: The interaction between joint injuries and posttraumatic osteoarthritis (PTOA) is generally thought to be mechanical in nature, however, surgical intervention has little effect on the development of PTOA. Little is known about the biological underpinning of how meniscus and anterior cruciate ligament (ACL) tears lead to cartilage degeneration. This review summarizes the latest findings regarding biological factors that influence how the knee responds to meniscus and ligament injuries, how meniscus and/or ACL tears turn the joint in the direction of PTOA and whether patient risk for PTOA after meniscus/ACL injury can be predicted. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00002281-900000000-9910
Publisher Site
http://dx.doi.org/10.1097/BOR.0000000000000566DOI Listing
January 2019
18 Reads

Lung transplantation in scleroderma: recent advances and lessons.

Curr Opin Rheumatol 2018 Nov;30(6):562-569

Division of Pulmonary and Critical Care, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Purpose Of Review: The purpose of this review is to highlight recent data regarding feasibility and outcomes following lung transplantation for patients with systemic sclerosis related pulmonary disease as well as to emphasize areas of uncertainly in need of further study. We include a description of our centre's approach to lung transplant evaluation and posttransplant management in this complex patient population.

Recent Findings: Historical data have demonstrated that patients with scleroderma have an increased risk of complications following lung transplantation owing to the multisystem nature of disease, particularly concurrent gastrointestinal, cardiac and renal involvement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000546DOI Listing
November 2018
13 Reads

Antisynthetase syndrome pathogenesis: knowledge and uncertainties.

Curr Opin Rheumatol 2018 Nov;30(6):664-673

Sorbonne Universités, Université Pierre et Marie Curie Université Paris 06, INSERM U1135, CNRS ERL8255, Centre d'Immunologie et des Maladies Infectieuses.

Purpose Of Review: Antisynthetase syndrome (ASyS) is an acquired myopathy characterized by the presence of myositis-specific autoantibodies directed against tRNA-synthetases. ASyS is potentially life threatening due to lung involvement and treatment remains a challenge to date. With symptoms not limited to muscles but also involving lung, skin and joints, ASyS appears specific and has a particular pathogenesis, different from the other inflammatory myopathies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000555DOI Listing
November 2018
2 Reads

Peculiar clinicopathological features of immune-mediated necrotizing myopathies.

Curr Opin Rheumatol 2018 Nov;30(6):655-663

Sorbonne Universités, AP-HP, Hôpital Pitié Salpêtrière, Département de médecine Interne et Immunologie Clinique, Centre de Référence Maladies Neuro-Musculaires.

Purpose Of Review: In the past decade, immune-mediated necrotizing myopathies have emerged as a separate entity in the heterogenous group of autoimmune myopathies. This group is characterized by clinical manifestations restricted to the muscle tissue, and until recently, the definition was based on muscular pathological features.

Recent Findings: It was shown that they are the most severe autoimmune myopathies in term of muscle damages. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000547DOI Listing
November 2018
12 Reads

Gastrointestinal involvement in systemic sclerosis: diagnosis and management.

Curr Opin Rheumatol 2018 Nov;30(6):533-540

Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Purpose Of Review: This review provides important updates in systemic sclerosis (SSc)-related gastrointestinal disease, with a particular focus on the diagnosis and management of dysmotility.

Recent Findings: In the past 2 years, several studies were published that present interesting diagnostic insights into SSc and gastrointestinal dysmotility. Studies focusing on new therapies and the novel application of existing therapies, both in SSc and non-SSc-associated gastrointestinal dysmotility syndromes, demonstrate progress in the management of these challenging complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000545DOI Listing
November 2018
1 Read

Recent progress in systemic sclerosis-interstitial lung disease.

Curr Opin Rheumatol 2018 Nov;30(6):570-575

Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Purpose Of Review: Systemic sclerosis is a systemic autoimmune disorder wherein interstitial lung disease (ILD) is the major source or morbidity and mortality. Research into mechanisms of fibrosis and its intersection with autoimmunity, specifically lung fibrosis, has accelerated and been applied to autoimmune disorders such as scleroderma. This review highlights important emerging insights and treatment trials. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00002281-900000000-9910
Publisher Site
http://dx.doi.org/10.1097/BOR.0000000000000544DOI Listing
November 2018
7 Reads

T cells and cytokines in systemic sclerosis.

Curr Opin Rheumatol 2018 Nov;30(6):594-599

Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Purpose Of Review: Dysregulation of both the innate and the adaptive immune systems has been identified in systemic sclerosis (SSc). However, the mechanisms underlying aberrant immune cell function remain poorly understood. T cells represent a predominant cell type in the affected tissues of patients, particularly in the early inflammatory stage of the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000553DOI Listing
November 2018
1 Read

New insights in myositis-specific autoantibodies.

Curr Opin Rheumatol 2018 Nov;30(6):614-622

Unit of Rheumatology, Department of Medicine, University of Padova, Padova, Italy.

Purpose Of Review: The aim of this study was to provide the most recent evidence on clinical utility of myositis-specific autoantibodies (MSAs) in the management of patients with myositis.

Recent Findings: In the last few years, several evidences have emerged on the clinical and pathogenetic role of established and novel MSA. Antisynthetase antibodies represent a reliable biomarker for pulmonary involvement also in patients with connective tissue diseases other than myositis. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00002281-900000000-9910
Publisher Site
http://dx.doi.org/10.1097/BOR.0000000000000548DOI Listing
November 2018
10 Reads